VI
JAZZ icon

Versor Investments’s Jazz Pharmaceuticals JAZZ Stock Holding History

Versor Investments’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-11,200
Closed -$1.38M – 792
2023
Q4 		$1.38M Buy
11,200
+9,272
+481% +$1.16M 0.28% 67
2023
Q3 		$250K Sell
1,928
-4,200
-69% -$560K 0.05% 536
2023
Q2 		$760K Buy
6,128
+1,324
+28% +$178K 0.13% 141
2023
Q1 		$703K Sell
4,804
-727
-13% -$108K 0.09% 203
2022
Q4 		$881K Buy
+5,531
New +$811K 0.08% 184
2019
Q1 		– Sell
-3,700
Closed -$459K – 295
2018
Q4 		$459K Buy
+3,700
New +$549K 0.11% 176
2018
Q1 		– Sell
-4,644
Closed -$625K – 268
2017
Q4 		$625K Buy
+4,644
New +$644K 0.18% 153

Other funds holding JAZZ

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PCM
Polaris Capital Management Boston, Massachusetts $1.22B AUM 26.01% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Versor Investments's JAZZ Position: Q1 2024 in Review

Versor Investments sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2024, closing a stake of 11,200 shares — an estimated $1.38M sold.

Versor Investments first reported a position in JAZZ in Q4 2017 and held it in 7 quarters. The position peaked at $1.38M in Q4 2023. 480 funds tracked by Wall St. Rank hold JAZZ as of Q1 2024.

  • Versor Investments reported no remaining Jazz Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Versor Investments sold 11,200 Jazz Pharmaceuticals shares in Q1 2024, an estimated $1.38M.
  • Versor Investments first reported a position in Jazz Pharmaceuticals in Q4 2017 and held it in 7 quarters.
  • Versor Investments's Jazz Pharmaceuticals position peaked at $1.38M in Q4 2023.
  • 480 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2024.

Based on Versor Investments's 13F filing for Q1 2024, filed 13 May 2024.